Panaji Journal

Amyotrophic Lateral Sclerosis Market

(Albany, USA) DelveInsight’s “Amyotrophic Lateral Sclerosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Amyotrophic Lateral Sclerosis, historical and forecasted epidemiology as well as the Amyotrophic Lateral Sclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Amyotrophic Lateral Sclerosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Amyotrophic Lateral Sclerosis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Amyotrophic Lateral Sclerosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Amyotrophic Lateral Sclerosis market.

Request for a Free Sample Report @ Amyotrophic Lateral Sclerosis Market Forecast

Some facts of the Amyotrophic Lateral Sclerosis Market Report are:

• According to DelveInsight, Amyotrophic Lateral Sclerosis market is expected to grow at a decent CAGR by 2032.
• The Amyotrophic Lateral Sclerosis market size in the seven major markets was ~ USD 1,000 million in 2023.
• Leading Amyotrophic Lateral Sclerosis companies working in the market are Biogen, Ionis Pharmaceuticals, Ferrer Internacional S.A., AbbVie, Calico Life Sciences LLC, Genuv Inc., Kadimastem, Corcept Therapeutics, AL-S Pharma, Rapa Therapeutics LLC, Cytokinetics, MediciNova, Retrotope, Inc. Woolsey Pharmaceuticals, Sanofi, PTC Therapeutics, Helixmith Co., Ltd., Annexon, Inc., Denali Therapeutics Inc., Revalesio Corporation, Clene Nanomedicine, Ashvattha Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Procypra Therapeutics, Knopp Biosciences, InFlectis BioScience, AI Therapeutics, Inc., Cellenkos, ZZ Biotech, LLC, QurAlis Corporation, Alector Inc., NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Eledon Pharmaceuticals,  and others.
• Key Amyotrophic Lateral Sclerosis Therapies expected to launch in the market are BIIB067, FAB122, ABBV-CLS-7262, Trametinib, BIIB105, AstroRx, Dazucorilant, AP-101,  RAPA-501, ION-363, Reldesemtiv, MN-166, RT001, Fasudil,  SAR443820, PTC857, ANX005, DNL343, RNS60, BIIB100, CNMAu8, 18F-OP-801, Pegcetacoplan (APL-2), Cu(II)ATSM, KNS-760704, IFB-088, LAM-002A,  CK 0803, 3K3A-APC,  QRL-201, Dexpramipexole, AL001, PrimeC, BLZ945, AT-1501,  and others.
• On April 2024, Corcept Therapeutics announced results of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients With Amyotrophic Lateral Sclerosis (DAZALS)
• On March 2024, Verge Genomics announced results of a Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Lateral Sclerosis Followed by Long-Term Treatment.
• On October 2023, Phase 2, Proof-of-concept, Placebo Controlled, Randomized, Multi-centre, Double Blind Study of ZYIL1 to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Amyotrophic Lateral Sclerosis (ALS).
• On August 2023, AL-S Pharma announced results of a Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacodynamic Markers, and Pharmacokinetics of AP-101 in Patients With Familial Amyotrophic Lateral Sclerosis (fALS) and Sporadic Amyotrophic Lateral Sclerosis (sALS).
• In February 2023, NeuroSense Therapeutics Ltd. and QuantalX Neuroscience Ltd; the developer of Delphi-MD, a clinically objective neurodiagnostic medical device, announced a collaboration to improve early diagnosis and treatment of neurodegenerative diseases.In addition, the companies agreed that QuantalX’s Delphi-MD would be used for early diagnosis and ongoing monitoring of trial participants in NeuroSense’s planned future pivotal Phase III efficacy trial of PrimeC in people living with amyotrophic lateral sclerosis (ALS), pending the successful conclusion of its ALS Phase IIb trial.

Amyotrophic Lateral Sclerosis Overview

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord. ALS primarily affects the motor neurons responsible for controlling voluntary muscle movement, leading to muscle weakness, atrophy, and eventually paralysis.

The initial symptoms of ALS can vary, but commonly include muscle weakness, cramps, twitching (fasciculations), and difficulty with speaking, swallowing, or breathing. As the disease progresses, individuals may experience muscle stiffness, spasticity, and loss of motor control.

Learn more about Amyotrophic Lateral Sclerosis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market

Amyotrophic Lateral Sclerosis Market

The Amyotrophic Lateral Sclerosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Amyotrophic Lateral Sclerosis market trends by analyzing the impact of current Amyotrophic Lateral Sclerosis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Amyotrophic Lateral Sclerosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Amyotrophic Lateral Sclerosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Amyotrophic Lateral Sclerosis market in 7MM is expected to witness a major change in the study period 2020-2034.

Amyotrophic Lateral Sclerosis Epidemiology 

The Amyotrophic Lateral Sclerosis epidemiology section provides insights into the historical and current Amyotrophic Lateral Sclerosis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Amyotrophic Lateral Sclerosis market report also provides the diagnosed patient pool, trends, and assumptions. 

Explore more about Amyotrophic Lateral Sclerosis Epidemiology @ Amyotrophic Lateral Sclerosis Market Dynamics

Amyotrophic Lateral Sclerosis Drugs Uptake

This section focuses on the uptake rate of the potential Amyotrophic Lateral Sclerosis drugs recently launched in the Amyotrophic Lateral Sclerosis market or expected to be launched in 2020-2034. The analysis covers the Amyotrophic Lateral Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Amyotrophic Lateral Sclerosis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Amyotrophic Lateral Sclerosis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Amyotrophic Lateral Sclerosis Pipeline Development Activities 

The Amyotrophic Lateral Sclerosis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Amyotrophic Lateral Sclerosis key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Amyotrophic Lateral Sclerosis pipeline development activities @ https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market

Amyotrophic Lateral Sclerosis Therapeutics Assessment

Major key companies are working proactively in the Amyotrophic Lateral Sclerosis Therapeutics market to develop novel therapies which will drive the Amyotrophic Lateral Sclerosis treatment markets in the upcoming years are Biogen, Ionis Pharmaceuticals, Ferrer Internacional S.A., AbbVie, Calico Life Sciences LLC, Genuv Inc., Kadimastem, Corcept Therapeutics, AL-S Pharma, Rapa Therapeutics LLC, Cytokinetics, MediciNova, Retrotope, Inc. Woolsey Pharmaceuticals, Sanofi, PTC Therapeutics, Helixmith Co., Ltd., Annexon, Inc., Denali Therapeutics Inc., Revalesio Corporation, Clene Nanomedicine, Ashvattha Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Procypra Therapeutics, Knopp Biosciences, InFlectis BioScience, AI Therapeutics, Inc., Cellenkos, ZZ Biotech, LLC, QurAlis Corporation, Alector Inc., NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Eledon Pharmaceuticals,  and others.

Get the Detailed TOC of the Amyotrophic Lateral Sclerosis Market report here @ https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market

Amyotrophic Lateral Sclerosis Report Key Insights

1. Amyotrophic Lateral Sclerosis Patient Population

2. Amyotrophic Lateral Sclerosis Market Size and Trends

3. Key Cross Competition in the Amyotrophic Lateral Sclerosis Market

4. Amyotrophic Lateral Sclerosis Market Dynamics (Key Drivers and Barriers)

5. Amyotrophic Lateral Sclerosis Market Opportunities

6. Amyotrophic Lateral Sclerosis Therapeutic Approaches

7. Amyotrophic Lateral Sclerosis Pipeline Analysis

8. Amyotrophic Lateral Sclerosis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Amyotrophic Lateral Sclerosis Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Amyotrophic Lateral Sclerosis Competitive Intelligence Analysis

4. Amyotrophic Lateral Sclerosis Market Overview at a Glance

5. Amyotrophic Lateral Sclerosis Disease Background and Overview

6. Amyotrophic Lateral Sclerosis Patient Journey

7. Amyotrophic Lateral Sclerosis Epidemiology and Patient Population

8. Amyotrophic Lateral Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Amyotrophic Lateral Sclerosis Unmet Needs

10. Key Endpoints of Amyotrophic Lateral Sclerosis Treatment

11. Amyotrophic Lateral Sclerosis Marketed Products

12. Amyotrophic Lateral Sclerosis Emerging Therapies

13. Amyotrophic Lateral Sclerosis Seven Major Market Analysis

14. Attribute Analysis

15. Amyotrophic Lateral Sclerosis Market Outlook (7 major markets)

16. Amyotrophic Lateral Sclerosis Access and Reimbursement Overview

17. KOL Views on the Amyotrophic Lateral Sclerosis Market

18. Amyotrophic Lateral Sclerosis Market Drivers

19. Amyotrophic Lateral Sclerosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services